BiotechTube

Bortezomib + Cyclophosphamide + Dexamethasone + Isatuximab

Phase 1Active
1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AL Amyloidosis

Conditions

AL Amyloidosis

Trial Timeline

Apr 28, 2021 → Jul 24, 2026

NCT ID
NCT04754945

About Bortezomib + Cyclophosphamide + Dexamethasone + Isatuximab

Bortezomib + Cyclophosphamide + Dexamethasone + Isatuximab is a phase 1 stage product being developed by Sanofi for AL Amyloidosis. The current trial status is active. This product is registered under clinical trial identifier NCT04754945. Target conditions include AL Amyloidosis.

What happened to similar drugs?

0 of 12 similar drugs in AL Amyloidosis were approved

Approved (0) Terminated (2) Active (10)
🔄NTLA-2001 + PlaceboRegeneron PharmaceuticalsPhase 3
🔄PatisiranAlnylam PharmaceuticalsPhase 3
🔄PatisiranAlnylam PharmaceuticalsPhase 3
🔄Nucresiran + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3
🔄Vutrisiran + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3
🔄Placebo + PatisiranAlnylam PharmaceuticalsPhase 3
🔄patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04754945Phase 1Active

Competing Products

20 competing products in AL Amyloidosis

See all competitors
ProductCompanyStageHype Score
ZN-d5Zentalis PharmaceuticalsPhase 1/2
22
VELCADEJohnson & JohnsonPhase 1/2
32
ABBV-383 (Etentamig)AbbViePhase 1/2
39
Venetoclax + Dexamethasone + DaratumumabAbbViePhase 1/2
24
Eplontersen Solution for InjectionAstraZenecaPhase 1
29
Treatment of transthyretin (ATTR) amyloidosis in observational study settingAstraZenecaPre-clinical
33
Carfilzomib + DexamethasoneAmgenPhase 1
29
IdelalisibGilead SciencesPhase 2
27
TafamidisPfizerPre-clinical
26
TafamidisPfizerPre-clinical
30
Fx-1006APfizerPhase 2
35
tafamidisPfizerPre-clinical
26
Cyclophosphamide + Dexamethasone + Elotuzumab + LenalidomideBristol Myers SquibbPhase 2
31
IsatuximabBristol Myers SquibbPhase 2
42
Bendamustine Hydrochloride + IsatuximabSanofiPhase 2
27
NC-503 (Anti-amyloidotic (AA) Agent)GSK plcPhase 2/3
38
NTLA-2001 + PlaceboRegeneron PharmaceuticalsPhase 3
44
LinvoseltamabRegeneron PharmaceuticalsPhase 1/2
39
ALN-TTR01 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
26
PatisiranAlnylam PharmaceuticalsPhase 3
37